Clinical Translation of a viral-based Individualized Cancer Vaccine – Insights from the TG4050 Program to guide future development of Personalized Immunotherapies
• Presenting updated phase I translational data from TG4050, an individualized neoantigen therapeutic vaccine developed for solid tumors based on Transgene’s myvac technology and powered by NEC’s artificial intelligence (AI) expertise
• Profiling of the neoantigen-specific T cell response after adjuvant TG4050 vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC